Urogen Pharma (NASDAQ:URGN) Receives “Buy” Rating from D. Boral Capital

Urogen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $33.00 price objective on the stock. D. Boral Capital’s price objective would suggest a potential upside of 94.12% from the stock’s previous close.

Several other research firms also recently commented on URGN. Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a report on Monday, March 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, January 21st. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $33.29.

Urogen Pharma Price Performance

NASDAQ:URGN opened at $17.00 on Tuesday. Urogen Pharma has a one year low of $3.42 and a one year high of $30.00. The company’s 50-day simple moving average is $19.84 and its 200 day simple moving average is $20.75. The firm has a market capitalization of $827.56 million, a P/E ratio of -5.31 and a beta of 1.34.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.12. The company had revenue of $37.84 million during the quarter, compared to the consensus estimate of $39.92 million. On average, equities research analysts expect that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Activity at Urogen Pharma

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the sale, the general counsel directly owned 51,326 shares in the company, valued at approximately $1,010,608.94. This trade represents a 12.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 7,373 shares of Urogen Pharma stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $145,174.37. Following the completion of the sale, the insider directly owned 144,985 shares of the company’s stock, valued at approximately $2,854,754.65. The trade was a 4.84% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Urogen Pharma

Institutional investors have recently modified their holdings of the business. Walleye Capital LLC bought a new position in Urogen Pharma during the second quarter valued at approximately $4,742,000. Squarepoint Ops LLC grew its position in Urogen Pharma by 187.8% during the second quarter. Squarepoint Ops LLC now owns 94,309 shares of the company’s stock valued at $1,292,000 after buying an additional 61,545 shares during the period. JPMorgan Chase & Co. grew its position in Urogen Pharma by 36.9% during the third quarter. JPMorgan Chase & Co. now owns 534,545 shares of the company’s stock valued at $10,664,000 after buying an additional 144,181 shares during the period. GSA Capital Partners LLP purchased a new stake in Urogen Pharma during the third quarter valued at approximately $977,000. Finally, NEOS Investment Management LLC bought a new position in Urogen Pharma in the third quarter worth approximately $1,007,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.